

# Conference Agenda

**FRIDAY  
MARCH 31**

## **Session 1: MCGI Updates**

Session Chair: Leah Graham,  
Ph.D. | Associate Director, MCGI |  
The Jackson Laboratory



## **Session 2: Patient Experience and Advocacy**

Session Chair: David Thomas,  
FRACP, Ph.D. | Head, Genomic  
Cancer Medicine | Omico:  
Australian Genomic Cancer  
Medicine Centre

## **GTB Case Discussion 1**

Session Chairs: Emily Edelman,  
M.S., CGC | Director, Clinical  
Education Program | The Jackson  
Laboratory

Kate Reed, M.P.H., Sc.M. CGC |  
Director, Precision Oncology  
Education, Clinical Education  
Program | The Jackson Laboratory

## **Session 3: The Future of Molecular Testing in Treatment Decisions**

Session Chair: Lindsey Kelley,  
M.P.H., M.S., CGC | Genomic  
Navigator, MCGI | The Jackson  
Laboratory



## **12:00 PM Welcome Remarks**

Jens Rueter, M.D. | Medical Director, MCGI | The Jackson Laboratory

## **12:05 PM–12:30 PM Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2/3 amplification, overexpression, or mutation: results from the TAPUR study**

Sarah Sinclair, D.O. | Medical Director of Hematology & Oncology, Director of Clinical Research | Northern Light Cancer Care

## **12:30 PM–12:55 PM Urban-rural and socioeconomic differences in patient perceptions of genomic tumor testing**

Eric Anderson, Ph.D. | Faculty Scientist |  
MaineHealth Institute for Research

## **1:00 PM–1:20 PM Overarching patient experience: balance of efficacy and side effects of targeted therapy**

Meghna Trivedi, M.D., M.S. | Assistant Professor | Columbia University Irving Medical Center

## **1:20 PM–1:40 PM Cancer patient experience on decision making and advocacy**

Barbara Segarra-Vázquez, D.H.Sc | Professor and Principal Investigator at CRECD NIH Grant | University of Puerto Rico

## **1:40 PM–2:00 PM Panel Discussion: Patient Experience and Advocacy**

## **2:30 PM–3:30 PM MAPK Pathway Alteration**

Jill M. Kolesar, Pharm.D., M.S., BCPS, FCCP | Professor, Pharmacy and Medicine | University of Kentucky

Kelsey Fusco, M.S., CGC | Genetic Counselor | New England Cancer Specialists

Sara Patterson, Ph.D. | Associate Director, Clinical Genomics Informatics Products | The Jackson Laboratory

Cara Statz, Ph.D. | Senior Clinical Analyst | The Jackson Laboratory

## **3:40 PM–4:00 PM Engaging patients in genomic medicine**

Stacy W. Gray, M.D., A.M. | Deputy Director, Center for Precision Medicine and Division Chief, Clinical Cancer Genomics | City of Hope

## **4:00 PM–4:20 PM Artificial intelligence-assisted cancer genomics: successes and limitations**

Christopher D. Gocke, M.D. | Associate Professor of Pathology, Oncology, and Genetic Medicine | Johns Hopkins University School of Medicine

## **4:20 PM–4:40 PM Panel Discussion: The Future of Molecular Testing in Treatment Decisions**

# SATURDAY APRIL 1

## **Session 4: Insights into the Genetics of Ovarian Cancer and Oncofertility**

Session Chair: Leslie Bradford, M.D. | Gynecologic Oncologist | MaineHealth



## **Session 5: New Developments in Translational Research**

Session Chair: Edison T. Liu, M.D. | Professor and President Emeritus | The Jackson Laboratory

## **Session 6: New Developments in Clinical Care**

Session Chair: Christian Thomas, M.D., FASCO | Director, Clinical Research | New England Cancer Specialists

## **GTB Case Discussion 2**

Session Chairs: Emily Edelman, M.S., CGC | Director, Clinical Education Program | The Jackson Laboratory

Kate Reed, M.P.H., Sc.M. CGC | Director, Precision Oncology Education, Clinical Education Program | The Jackson Laboratory

## **Session 7: Clinical Trials for Rural Healthcare**

Session Chair: Vatche Tchekmedyan, M.D. | Hematology/Medical Oncologist | MaineHealth

## **8:30 AM–8:50 AM Preservation of reproductive health and fertility in cancer survivors: from bench to bedside**

Ewelina Bolcun-Filas, Ph.D. | Associate Professor | The Jackson Laboratory

## **8:50 AM–9:10 AM Precision medicine in ovarian cancer: where we are now and where we are going**

Charlie Gourley, Ph.D. | Professor and Honorary Consultant, Medical Oncology, Clinical Director, Cancer Research UK Scotland Centre, Director, Nicola Murray Centre for Ovarian Cancer Research | The University of Edinburgh

## **9:10 AM–9:30 AM Panel Discussion: Insights into the Genetics of Ovarian Cancer and Oncofertility**

## **9:45 AM–10:05 AM Dissecting response to treatment in adult patients with a glioma**

Roel Verhaak, Ph.D., M.Sc. | Professor and Associate Director, Computational Biology | The Jackson Laboratory

## **10:05 AM–10:25 AM Imaging analysis to guide precision medicine**

Jeffrey Chuang, Ph.D. | Professor | The Jackson Laboratory

## **10:25 AM–10:45 AM Panel Discussion: New Developments in Translational Research**

## **11:00 AM–11:20 AM Tackling unmet need: the role of precision medicine in rare cancers**

David Thomas, FRACP, Ph.D. | Head, Genomic Cancer Medicine | Omico: Australian Genomic Cancer Medicine Centre

## **11:20 AM–11:40 AM Novel approaches to RAS targeting**

Ryan Sullivan, M.D. | Associate Professor | Massachusetts General Hospital

## **11:40 AM–12:00 PM Panel Discussion: New Developments in Clinical Care**

## **1:00 PM–2:00 PM DNA Damage Repair**

Christine Walko, Pharm.D., BCOP, FCCP | Senior Member, Individualized Cancer Management | Moffitt Cancer Center

Jill M. Kolesar, Pharm.D., M.S., BCPS, FCCP | Professor, Pharmacy and Medicine | University of Kentucky

Kelsey Fusco, M.S., CGC | Genetic Counselor | New England Cancer Specialists

Sara Patterson, Ph.D. | Associate Director, Clinical Genomics Informatics Products | The Jackson Laboratory

Cara Statz, Ph.D. | Senior Clinical Analyst | The Jackson Laboratory

## **2:15 PM–2:35 PM Clinical trial access: focus on rural populations**

Olwen Hahn, M.D. | Associate Professor, Medicine | The University of Chicago

## **2:35 PM–2:55 PM The ASCO TAPUR study: learning from precision medicine in practice**



Richard Schilsky, M.D., FACP, FSCT, FASCO | Principal Investigator, ASCO TAPUR Study | American Society of Clinical Oncology

**2:55 PM–3:15 PM**    **Quality initiative to assess the value of multidisciplinary genomic tumor board (mGTB) and feasibility of upfront incorporation of comprehensive genomic testing for brain tumors**

Christine Lu-Emerson, M.D. | Neuro-Oncologist | MaineHealth

**3:15 PM–3:35 PM**    **Panel Discussion: Clinical Trials for Rural Healthcare**

**3:35 PM–3:45 PM**    **Closing**